Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a very effective
target for the treatment of type 2 diabetes mellitus at clinical. In addition, it can promote
insulin secretion with low potential toxicity, and half-life is shorter than Linagliptin.